The biotechnology sector has certainly become one of the most exciting sectors of the market. It is known for giving its investors substantial returns in a short period of time. Usually, it only takes one FDA catalyst to send their share prices soaring. Last year was a significant year for biotechs, U.S. drug approvals reached a twenty-one-year high. Forty-six novel medications gained approval, most in rare diseases and cancer sub-types, compared to just twenty-one medications the year prior. To date, thirty novel drugs have gained the FDA’s approval this year and the rapid momentum of the industry is what continues to appeal to investors. Ten companies whose drugs have gained FDA Approval this year include: · AAA USA Inc (AAAP) · Amicus Therapeutics (FOLD) · Anylam Pharma Inc (ALNY) · Gilead Sciences Inc (GILD) · Janssen Biotech (subsidiary of JNJ) · Merck Sharp Dohme’s (MRK) · Teva Pharmaceutical USA (TEVA) · Ultragenyx Pharmaceuticals Inc (RARE) · Vertex Pharms Inc (VRTX) As we see the number of drug approvals increase, spotting companies with potential in their pipelines is key. Here are three bio-pharmaceutical companies that may have a good chance of obtaining FDA approval one of their drugs. Click Here To See 3 Biotech Stocks That Could Skyrocket This Year.